Business UpdateMay 27, 2026, 07:05 AM
Maze Therapeutics CEO to Present at Jefferies & Goldman Sachs
AI Summary
Maze Therapeutics announced that its Chief Executive Officer, Jason Coloma, Ph.D., will participate in two upcoming investor conferences. He is scheduled to present at the 2026 Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10. The company, a clinical-stage biopharmaceutical firm, is focused on developing small molecule precision medicines for kidney and metabolic diseases, with key programs MZE829 and MZE782 in Phase 2 development. Live webcasts of the presentations will be accessible via the company's investor relations website.
Key Highlights
- CEO Jason Coloma to present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:45 p.m. ET.
- CEO Jason Coloma to present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 8:40 a.m. ET.
- Live webcasts of both events will be available in the Investors section of the company's website.
- Webcasts will be archived for 60 days following the presentations.
- Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for kidney and metabolic diseases.
- Lead pipeline programs include MZE829 (Phase 2 for AMKD) and MZE782 (advancing to Phase 2 for PKU and CKD).
Price Impact
More from MAZE